Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Aura Biosciences reported a net loss of $33.7 million for the first quarter of 2026, compared to $27.5 million in the same period last year. The company completed an oversubscribed $280.8 million equity financing, which, after expenses, provided approximately $280.8 million in net proceeds. This strengthens the balance sheet and extends the cash runway into the second half of 2028. Natalie Holles was appointed as the new CEO and President, effective April 30, 2026, succeeding Elisabet de los Pinos, Ph.D., who stepped down from her roles.
Key figures
- Eps Beat
- 0
- Revenue
- 0
- Guidance
- cash runway into the second half of 2028
- Revenue Yoy
- 0
- Net loss
- 33685000
- G and a expenses
- 6906000
- R and d expenses
- 27960000
- Marketable securities
- 29940000
- Repurchased shares cost
- 39000000
- Cash and cash equivalents
- 84793000
- Net proceeds from offering
- 280800000
- Weighted average common stock outstanding
- 67447576
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.